Adding immune modulators to targeted therapy, according to a trial, did not increase survival in thyroid cancer patients who are difficult to treat.

Published Date: 06 Sep 2023

A targeted tyrosine kinase inhibitor (TKI) should be used in combination with an immunomodulatory agent, according to the findings of a multicenter phase II clinical trial directed by the University of Chicago Medicine Comprehensive Cancer Center.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers find distinct cell receptors with the potential for new treatments.

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Too Many Chest CTs for Incidental Lung Nodules?

5.

Global warming could be driving up women's cancer risk, find researchers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot